Inobrodib: A New Oral Myeloma Treatment with Dr. Nisha Joseph

A new oral myeloma treatment is now in development. It doesn't work like anything else in your treatment history and has activity in patients who've run out of options. Join us as Dr. Nisha Joseph of Emory's Winship Cancer Institute breaks down how Inobrodib works, who it might help, and where it fits in the future of myeloma care.

Thank you to our sponsor for this episode

In this episode of the HealthTree Podcast for Multiple Myeloma, host Jenny Ahlstrom is joined by Dr. Nisha Joseph, MD, Emory University, to discuss inobrodib — a novel oral P300 inhibitor being tested in multiple myeloma and other blood cancers. Dr. Joseph explains how this first-in-class epigenetic modulator works differently from other myeloma therapies: rather than directly killing myeloma cells, it changes the way the cells produce proteins that keep them alive, targeting key regulators like IRF4 and MYC that have historically been very difficult to hit. Because inobrodib doesn't rely on T cell function, it can work effectively even after patients have been exposed to T cell-redirecting therapies like CAR T-cell therapy and bispecific antibodies, a growing patient population as these therapies are used earlier in treatment. 

The conversation focuses on the DOMMINO-1 trial, a Phase II study evaluating inobrodib in combination with pomalidomide and dexamethasone (InoPd) for heavily pretreated patients who are refractory to anti-CD38 antibodies and to pomalidomide, and who have received a BCMA bispecific antibody. Early data show a compelling overall response rate around 64-65% in this late-relapse population, with responses seen even in patients previously refractory to pomalidomide — suggesting inobrodib may resensitize myeloma cells to IMiD therapy. Dr. Joseph also discusses the practical benefits of an all-oral regimen for patients in rural or community settings who face access and travel barriers, side effects including cytopenias and muscle cramping that improved at the selected 20 mg dose, and the upcoming Phase III DOMMINO-2 trial that will randomize patients between InoPd and standard of care. Blood Cancer Awareness Month begins September 1st, with HealthTree launching a campaign to help patients create Personal Health Records to own their story, personalize their support, and power the cure.